INTRODUCTION {#sec1_1}
============

Reactive arthritis (ReA), also known as post-infectious arthritisis, is a spondyloarthropathic disorder characterized by inflammation of the joints and tissues occurring after gastrointestinal or genitourinary infections ([@B1]-[@B3]). The most common enteric bacterial pathogens that have been implicated in ReA include *Salmonella*, *Shigella*, and *Campylobacter* ([@B4]).

There is no diagnostic test for ReA; it is based entirely on clinical characteristics and, thus, is subject to clinical opinion ([@B5]). In addition, there are no established criteria for ReA diagnosis. Therefore, cases include a wide range of symptoms and definitions, some of which resemble other spondyloarthropathic disorders ([@B1],[@B5]). A definite time period from infection to the onset of ReA has not been established which contributes to significant uncertainty and inconsistency between studies. This discordance has led to variability in incidence estimates for reactive arthritis ([@B1],[@B3]).

Since there is considerable inconsistency in the diagnosis of ReA, it is important to determine the burden of reactive arthritis due to enteric infections, using standard criteria. To our knowledge, this is the first systematic review of worldwide data that use well-defined criteria to establish the global incidence of ReA for each of the three most commonly-associated pathogens.

MATERIALS AND METHODS {#sec1_2}
=====================

We conducted a systematic literature review in Embase, PubMed, and Scopus databases, using all combinations of applicable MeSH and general terms for ReA, *Campylobacter*, *Salmonella*, and *Shigella* ([Table 1a-1c](#T1a){ref-type="table"}). Additional articles were also retrieved from hand-searching reference lists of all articles selected for inclusion in the study. We sought to identify eligible case-control and prospective cohort studies that were published as of September 2011 in all languages. The inclusion criteria were laboratory confirmation of *Campylobacter*, *Salmonella*, or *Shigella* via stool or blood culture and ascertainment of ReA status within one year of infection. Prospective cohorts ascertained the clinical development of reactive arthritis via personal interview or chart reviews of individuals with laboratory-confirmed infections. For case-control studies, we searched for ones that tested for the presence of one of the selected ReA-triggering bacteria in both cases and controls. Cases had to be selected on the basis of ReA diagnosis with appropriate controls included.

###### 

Database search terms

  Table 1a          Embase                                                                                                                                 PubMed                                                                                                                                                                                                                                                                             Scopus
  ----------------- -------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Campylobacter*   'reactive arthritis'/exp OR 'reactive arthritis' AND ('campylobacter'/exp OR 'campylobacter') AND \[humans\]/lim AND \[english\]/lim   ("arthritis, reactive" \[MeSH Terms\] OR ("arthritis" \[All Fields\] AND "reactive" \[All Fields\]) OR "reactive arthritis" \[All Fields\] OR ("reactive" \[All Fields\] AND "arthritis" \[All Fields\])) AND ("campylobacter" \[MeSH Terms\] OR "campylobacter" \[All Fields\])   TITLE-ABS-KEY(\[40\] OR {Reactive Arthritides} OR {Reactive Arthritis} OR {Post-Infectious Arthritis} OR {Post Infectious Arthritis} OR {Postinfectious Arthritis} OR {Arthritis Post-Infectious} OR {Arthritides Post-Infectious} OR {Arthritis Post Infectious} OR {Post-Infectious Arthritides} OR {Arthritis Postinfectious} OR {Arthritides Postinfectious} OR {Postinfectious Arthritides} OR {Reiter Syndrome} OR {Syndrome Reiter} OR {Reiter\'s Disease} OR {Disease Reiter\'s} OR {Reiters Disease} OR {Reiter Disease} OR {Disease Reiter}) AND TITLE-ABS-KEY ({campylobacter} OR {Campylobacter coli} OR {Campylobacter fetus} OR {Campylobacter hyointestinalis} OR {Campylobacter jejuni} OR {Campylobacter lari} OR {Campylobacter rectus} OR {Campylobacter sputorum} OR {Campylobacter upsaliensis}) AND (LIMIT-TO(LANGUAGE,"English"))
  Table 1b          Embase                                                                                                                                 PubMed                                                                                                                                                                                                                                                                             Scopus
  *Salmonella*      'reactive arthritis'/exp OR 'reactive arthritis' AND ('salmonella'/exp OR 'salmonella') AND \[humans\]/lim AND \[english\]/lim         ("arthritis, reactive" \[MeSH Terms\] OR ("arthritis" \[All Fields\] AND "reactive"\[All Fields\]) OR "reactive arthritis" \[All Fields\] OR ("reactive" \[All Fields\] AND "arthritis"\[All Fields\])) AND ("salmonella" \[MeSH Terms\] OR "salmonella" \[All Fields\])           TITLE-ABS-KEY({Arthritides Reactive} OR {Reactive Arthritides} OR {Reactive Arthritis} OR {Post-Infectious Arthritis} OR {Post Infectious Arthritis} OR {Postinfectious Arthritis} OR {Arthritis Post-Infectious} OR {Arthritides Post-Infectious} OR {Arthritis Post Infectious} OR {Post-Infectious Arthritides} OR {Arthritis Postinfectious} OR {Arthritides Postinfectious} OR {Postinfectious Arthritides} OR {Reiter Syndrome} OR {Syndrome Reiter} OR {Reiter\'s Disease} OR {Disease Reiter\'s} OR {Reiters Disease} OR {Reiter Disease} OR {Disease Reiter}) AND TITLE-ABS-KEY ({Salmonella} OR {Salmonella arizonae} OR {Salmonella enterica} OR {Salmonella enteritidis} OR {Salmonella paratyphi A} OR {Salmonella paratyphi B} OR {Salmonella paratyphi C} OR {Salmonella typhi} OR {Salmonella typhimurium}) AND (LIMIT-TO (LANGUAGE,"English"))
  Table 1c          Embase                                                                                                                                 PubMed                                                                                                                                                                                                                                                                             Scopus
  *Shigella*        'reactive arthritis'/exp OR 'reactive arthritis' AND ('shigella'/exp OR 'shigella') AND \[humans\]/lim AND \[english\]/lim             ("arthritis, reactive" \[MeSH Terms\] OR ("arthritis" \[All Fields\] AND "reactive" \[All Fields\]) OR "reactive arthritis" \[All Fields\] OR ("reactive" \[All Fields\] AND "arthritis" \[All Fields\])) AND ("shigella" \[MeSH Terms\] OR "shigella" \[All Fields\])             TITLE-ABS-KEY({Arthritides Reactive} OR {Reactive Arthritides} OR {Reactive Arthritis} OR {Post-Infectious Arthritis} OR {Post Infectious Arthritis} OR {Postinfectious Arthritis} OR {Arthritis Post-Infectious} OR {Arthritides Post-Infectious} OR {Arthritis Post Infectious} OR {Post-Infectious Arthritides} OR {Arthritis Postinfectious} OR {Arthritides Postinfectious} OR {Postinfectious Arthritides} OR {Reiter Syndrome} OR {Syndrome Reiter} OR {Reiter\'s Disease} OR {Disease Reiter\'s} OR {Reiters Disease} OR {Reiter Disease} OR {Disease Reiter}) AND TITLE-ABS-KEY ({shigella} OR {shigella boydii} OR {shigella dysenteriae} OR {shigella flexneri} OR {shigella sonnei} AND (LIMIT-TO(LANGUAGE,"English"))

We excluded studies that did not confirm the presence of gastrointestinal pathogens via laboratory methods, articles that did not specify the time lag between infection and the ascertainment of ReA, case reports, and review articles without original data. Articles with less than 15 subjects were also excluded. Full manuscripts were obtained for all eligible studies.

Statistical methods {#sec1_2_1}
-------------------

We fit the data to a logistic regression model ([@B6]) to calculate a weighted mean for the incidence of ReA associated with gastroenteritis ([@B7]).

RESULTS {#sec1_3}
=======

We identified 970 articles from Embase, PubMed, and Scopus databases that were screened for potential inclusion in the study ([Figure](#UF1){ref-type="fig"}). A total of thirty-six articles published between 1976 and 2010 met all inclusion criteria. These studies were conducted predominantly in Europe, with seven studies in North America (n=6) and Australia (n=1). The time to ascertainment of ReA or development of symptoms ranged from within a month to 1 year post-infection, and the sample-size for cohort studies ranged from 37 to 57,425. The results presented are based upon the pooled incidence rates only. Due to the lack of a standard definition of ReA, there was high heterogeneity between the studies (I-squared \>95%); therefore, the meta-analysis model was not a good fit for the data. No case-control studies were identified; thus, it was not possible to calculate the background rate of ReA and the attributable rate of ReA due to enteric infections.

![Literature review](jhpn0031-0299_uf01){#UF1}

Campylobacter {#sec1_3_1}
-------------

We identified 25 articles for a full manuscript review. Out of these, 14 cohort studies ([@B8]-[@B21]) were included in the final assessment of the incidence of *Campylobacter-*associated reactive arthritis ([Table 2](#T2){ref-type="table"}). These cohort studies accounted for a total of 63,206 patients with *Campylobacter* infection, of which 573 progressed to reactive arthritis. The other 11 articles were excluded after reviewing the manuscripts due to either insufficient data on laboratory confirmation methods for all subjects, mixed bacterial isolates, information on time to ReA diagnosis missing or exceeding 12 months or they did not meet the other requirements for the study ([@B22],[@B23]). The calculated pooled incidence rate was 0.009 (95% CI 0.009-0.010). This is an incidence of 9 reactive arthritis cases per 1,000 cases of *Campylobacter* infection.

###### 

Cohort studies for *Campylobacter*

  Author, Publication year   Country         Study duration       Population with *Campylobacter* infection   Population that developed ReA   Time from infection to ReA Diagnosis
  -------------------------- --------------- -------------------- ------------------------------------------- ------------------------------- ----------------------------------------------
  Bremell, 1991              Sweden          1986-1987            66                                          5                               \<1 month
  Eastmond, 1983             Scotland        1979                 130                                         2                               \<2 months
  Hannu, 2002                Finland         Apr 1997-Sept 1998   609                                         45                              \<2 months
  Johnsen, 1983              Norway          Jun 1980-Sep 1981    37                                          5                               3 days-2 weeks
  Kosunen, 1981              Finland         Jul 1978-Dec 1979    342                                         8                               4 days-4 weeks
  Locht, 2002                Denmark         1997-1999            173                                         27                              \<4 weeks
  Petersen, 1996             Denmark         Jan 1991-Dec 1993    41                                          0                               NA
  Pitkanen, 1983             Sweden          Jul 1978 -Jun 1981   188                                         9                               1-3 week(s)
  Ponka, 1984                Finland         Jul 1978-Jun 1981    283                                         6                               2-3 weeks
  Rees, 2004                 United States   Apr 1998-Mar 1999    324                                         9                               2 months
  Schiellerup, 2008          Denmark         Jan 2002-Nov 2003    1,003                                       131                             \<4 weeks of infection
  Schönberg-Norio, 2010      Finland         Jul 2002-Sep 2002    201                                         8                               Median: 7 days (range:: 0-60 days)
  Ternhag, 2008              Sweden          1997-2004            57,425                                      15                              \<12 months
  Townes, 2008               United States   Mar 2002-Aug 2004    2384                                        302                             Median/mean: 16/18 days; (Range: 0-180 days)

Salmonella {#sec1_3_2}
----------

We identified 34 articles for a full manuscript review. Out of these, 16 cohort studies ([@B14],[@B17],[@B18],[@B20],[@B21],[@B24]-[@B34]) were included in the final assessment of the incidence of *Salmonella*-associated reactive arthritis ([Table 3](#T3){ref-type="table"}). These cohort studies accounted for a total of 39,148 patients with *Salmonella* infection, of which 474 progressed to reactive arthritis cases. Excluded articles did not contain relevant information or the time to ReA diagnosis was missing or exceeding 12 months, or data on laboratory confirmation methods for all subjects were insufficient. The calculated pooled incidence rate was 0.012 (95% CI 0.011-0.013). This is an incidence of 12 reactive arthritis cases per 1,000 cases of *Salmonella* infection.

Shigella {#sec1_3_3}
--------

We identified 15 articles for full manuscript review. Out of these, 7 cohort studies ([@B14],[@B17],[@B18],[@B20],[@B21],[@B35],[@B36]) were included in the final assessment of the incidence of *Shigella*-induced reactive arthritis ([Table 4](#T4){ref-type="table"}). These studies accounted for a total of 4,636 patients with *Shigella* infection, of which 56 reactive arthritis cases were found. The seven articles were excluded due to insufficient information either on laboratory confirmation for all subjects or ReA status, or data on time to ReA diagnosis was missing. The calculated pooled incidence rate was 0.012 (95% CI 0.009-0.015). This is an incidence of 12 reactive arthritis cases per 1,000 cases of *Shigella* infection.

DISCUSSION {#sec1_4}
==========

We sought to characterize the incidence of ReA among cases of *Campylobacter*, *Salmonella*, and *Shigella*, using well-established criteria. Among the studies analyzed, ReA incidence ranged from 0-16%, 0.1-29%, and 0-12% among *Campylobacter*, *Salmonella* and *Shigella* infections respectively. The weighted mean incidence was 9, 12, and 12 ReA cases per 1,000 *Campylobacter*, *Salmonella* and *Shigella* infections respectively.

It has been noted that gender does not play a role in enteric disease-associated ReA, and adults compared to children, are more susceptible to ReA following an enteric infection ([@B3]). In the present analysis, although only a small number of studies (Appendix) presented sufficient information to examine age-related ReA, we found a similar trend. The incidence of *Campylobacter*-associated ReA ranged from 8% to 16% with a median of 8% among adults compared to 0% to 6% with a median of 3% among children. *Salmonella-*associated ReA ranged from 1% to 24% with a median of 11% among adults compared to 0% to 12% with a median of 5% among children. *Shigella*-associated ReA ranged from 7% to 12% with a median of 9.5% among adults compared to 0% to 7% with a median of 3.5% among children. Although the burden of enteric infections is higher among children aged \<5 years ([@B37]), we found a lower incidence of reactive arthritis in children which could be due to the lack of full differentiation of their immune systems ([@B2],[@B32]). The information available on gender was insufficient to draw any conclusions.

###### 

Cohort studies for *Salmonella*

  Article             Country         Study duration      Population with *Salmonella i*nfection   Population that developed ReA   Time from infection to ReA diagnosis
  ------------------- --------------- ------------------- ---------------------------------------- ------------------------------- --------------------------------------------------------------
  Arnedo-Pena, 2010   Spain           Jul. 2005           67                                       6                               Mean: 28 days (Range: 3-83 days)
  Buxton, 2002        Canada          Dec 1999-Nov 2000   66                                       4                               \<3 months
  Hakansson, 1976     Sweden          1974                330                                      13                              1-2 weeks
  Hannu, 2002         Finland         1999                63                                       5                               Median: 2 days (Range 1-9 days)
  Lee, 2005           Australia       Feb-Jun 1999        261                                      38                              \<3 months
  Locht, 1993         Sweden          1990                113                                      17                              \<4 weeks
  Mattila, 1994       Finland         1992                246                                      17                              Median: 14 days (Range 7-40 days)
  Mattila, 1998       Finland         1994                191                                      22                              Median: 8.5 days (Range: 3-30 days)
  Petersen, 1996      Denmark         Jan 1991-Dec 1993   135                                      8                               During hospitalization, mean stay: 8 days (Range: 1-31 days)
  Rees, 2004          United States   Apr 1998-Mar 1999   100                                      2                               \<2 months
  Rudwaleit, 2001     Germany         1998                286                                      0                               \<4 months
  Samuel, 1995        United States   Jul 1993            495                                      6                               4-16 weeks
  Schiellerup, 2008   Denmark         Jan 2002-Nov 2003   619                                      104                             \<4 weeks
  Ternhag, 2008       Sweden          1997-2004           34,664                                   27                              \<12 months
  Townes, 2008        United States   Mar 2002-Aug 2004   1,356                                    204                             Median/mean: 16/18 days (Range: 0-180 days)
  Urfer, 2000         Switzerland     Oct-Nov 1983        156                                      1                               2 weeks

###### 

Cohort studies for *Shigella*

  Author              Country         Time of study        Population with *Shigella* infection   Population that developed ReA   Time from infection to ReA diagnosis
  ------------------- --------------- -------------------- -------------------------------------- ------------------------------- ---------------------------------------------
  Hannu, 2005         Finland         Oct 1996-Sept 2000   14                                     211                             \<2 months
  Lewis, 1982         United States   1980                 0                                      127                             NA
  Petersen, 1996      Denmark         Jan 1991-Dec 1993    0                                      4                               NA
  Rees, 2004          United States   Apr 1998-Mar 1999    1                                      81                              2 months
  Schiellerup, 2008   Denmark         Jan 2002-Nov 2003    10                                     102                             \<4 weeks
  Ternhag, 2008       Sweden          1997-2004            2                                      3,813                           \<12 months
  Townes, 2008        United States   Mar 2002-Aug 2004    29                                     298                             Median/mean: 16/18 days (Range: 0-180 days)

Our incidence estimates are comparable to previous estimates ([@B3],[@B18],[@B32],[@B35],[@B38]) but may under-estimate ReA cases for several reasons. ReA is considered to be a condition that may undergo spontaneous resolution. Therefore, individuals with milder cases of disease may not report it ([@B39]). In hospital-based studies, all patients are typically followed with either medical chart reviews or interviews with patients to assess the development of ReA, thereby minimizing loss to follow-up. This is in contrast to population-based studies where only a proportion of individuals with enteric infections may be assessed for ReA. For instance, such studies included in this review mailed out surveys to individuals with confirmed enteric infections to assess ReA symptoms or status, and only a proportion ranging from 31% to 90% (n=12) returned completed surveys. Incidence estimates were only based upon the sample that returned surveys which could bias our results in either direction if there was a differential response in those who developed ReA. We performed further sub-analyses, which excluded any study that had less than 70% of the subjects returning surveys (n=6), and the incidence estimates changed slightly with rates of 0.009 (95% CI 0.008-0.010) for *Campylobacter*, 0.011 (95% CI 0.010-0.012) for *Salmonella*, and 0.012 (95% CI 0.009-0.016) for *Shigella*.

Additionally, ReA is known to be a sequela of asymptomatic enteric infections ([@B2],[@B40]). In this review, the ReA incidence estimates were based upon laboratory-confirmed cases of infection and may have missed those cases of ReA with negative laboratory findings or asymptomatic presentations, thereby leading to an under-estimation of the incidence. However, in the absence of a well-designed epidemiological study or population-wide screening, it would be difficult to ascertain the exact incidence of ReA in both symptomatic and asymptomatic cases.

Pope and colleagues ([@B41]) performed a review of *Campylobacter*-associated ReA and found an incidence of 1-5%. However, this review did not establish any inclusion or exclusion criteria, and a distinction was made between acute and chronic ReA. The authors noted that cases of ReA varied considerably due to limitations in case assessment and diagnostics for ReA. This review suggested that young adults were more commonly affected by ReA. Genetics, specifically the presence of human leukocyte antigen (HLA)-B27, was found to have a mixed association with ReA. There is considerable discussion regarding HLA-B27 and its role in ReA ([@B1],[@B42]), and it is suggested that HLA-B27-positive individuals may have an increased susceptibility to ReA ([@B43]). However, the data on the association between HLA-B27 and ReA are conflicting with other studies finding no association ([@B10],[@B21]).

We believe our review improves upon estimate of Pope and colleagues by imposing a timeframe for ReA case ascertainment, i.e. within a year of infection, and utilizing inclusion/exclusion criteria to increase uniformity among the estimates for the three enteric infections. These criteria assist in addressing the major limitation in estimating incidence for ReA, i.e. the lack of diagnostic criteria. Time to ascertainment of ReA was based upon the majority of studies that assessed ReA within one year post-enteric infection. Defining time to ReA can play an important role in the incidence estimates, for instance, one study that initially assessed ReA status among individuals with enteric infections found no cases within 3 months of infection. However, a re-assessment 1 year later in the same population discovered incident ReA cases ([@B20]). This indicates a potential for the number of ReA cases to be under-estimated, especially among studies with shorter timeframes.

We did not assess the role of treatment of enteric infections on the development of ReA as the data were sparse concerning the patients who received treatment. It has, however, been suggested that incidence of ReA is lower where prompt treatment is available ([@B44]). The data in this area are also limited and inconsistent with a randomized clinical trial ([@B45]) finding no association between antibiotic treatment and improved arthritis outcomes.

We present the incidence of ReA as sequelae of *Campylobacter*, *Salmonella* and *Shigella* infections, using worldwide data. We conducted a thorough search and used strict inclusion and exclusion criteria; yet, even with this method, we acknowledge that these estimates will have limitations until better diagnostic criteria become available. This includes stricter criteria for appropriate time intervals between infection and symptoms of ReA as well as standardized tests to detect bacterial antigens.

ReA remains an important consequence of gastrointestinal infections. These infections due to food-borne pathogens have been estimated to afflict up to 30% of the population in developed countries, with much higher attack rates in the developing world ([@B46]). With incidence rates between 1 and 2%, ReA affects a significant number of individuals worldwide, especially in countries that have high rates of food- and water-borne infections. Although ReA can be self-limiting, resolving within 6 months, it has been estimated that up to 63% of afflicted persons will develop a chronic form of ReA ([@B3]). This not only increases morbidity, it imposes an additional socioeconomic burden on individuals and societies. This highlights the need for early diagnosis of disease, prompt and effective treatment, and prevention of enteric infections. Improved estimates on the global incidence of ReA would serve as a tool in the development of appropriate public-health prevention programmes.
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###### 

Age-related incidence of reactive arthritis

  Bacteria          Author          Adult incidence of ReA (%)   Child incidence of ReA (%)
  ----------------- --------------- ---------------------------- ----------------------------
  *Campylobacter*   Bremell, 1991   8                            0
  Eastmond, 1983    8               6                            
  Hannu, 2002       16              \-                           
  Johnsen, 1983     4               \-                           
  Kosunen, 1981     15              \-                           
  *Salmonella*      Hannu, 2002     12                           8
  Lee, 2005         9               0                            
  Locht, 1993       1               7                            
  Mattila, 1994     \-              0                            
  *Shigella*        Hannu, 2005     7                            0
  Lewis, 1982       12              7                            
